Chinese Pediatrics of Integrated Traditional and Western Medicine ›› 2016, Vol. 8 ›› Issue (6): 578-580.doi: 10.3969/j.issn.1674-3865.2016.06.008
Previous Articles Next Articles
SUN Honghua
Online:
Published:
Abstract: Objective: To investigate the effects of Jianpi Yifei oral solution on serum inflammatory cytokines and lung function in children with bronchial asthma at remission stage. Methods:Sixty children with bronchial asthma at remission stage admitted to Department of Pediatrics, the Second Hospital of Chaoyang, from January 2014 to February 2015, were included and divided randomly into observational group and control group, with 30 cases in each group. Jianpi Yifei oral solution and Budesonide powder for inhalation were administered for 3 months in the observational and control groups, respectively. Serum tumor necrosis factor-α and interleukin-6 and lung function were determined before and 3 months after treatment. Results:Serum tumor necrosis factor-α, interleukin-6, forced volume vital capacity, and forced expiratory volume in one second were significantly decreased after treatment, compared with before treatment(P<0.05). Serum tumor necrosis factor-α, interleukin-6, forced volume vital capacity, and forced expiratory volume in one second were similar before and after treatment(P>0.05). Conclusion:Jianpi Yifei oral solution can significantly inhibit airway inflammatory reaction and improve lung function in children with bronchial asthma at remission stage, and the effects are similar to those of hormone drugs.
Key words: Asthma, Tumor necrosis factor-α, Interleukin-6, Lung function, Children
SUN Honghua. Effect of Jianpi Yifei oral solution on airway inflammation and lung function in children with bronchial asthma at remission stage[J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2016, 8(6): 578-580.
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: https://www.zxek.net/EN/10.3969/j.issn.1674-3865.2016.06.008
https://www.zxek.net/EN/Y2016/V8/I6/578